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Amylin, a 37 amino acid product of pancreatic B-cells, inhibits insulin-stimulated radioglucose incorporation into muscle glycogen. In the current 
study, we exercised rats and then prelabelled the glycogen pool by infusing [3-3H]glucose along with glucose and insulin. Subsequent amylin 
administration increased the rate of appearance of tritiated water 6.4-fold, consistent with stimulation of glycogenolysis and passage of the released 
moieties through the hexose + triose step of glycolysis. Further, there was an increase in plasma [3-3H]glucose after amylin, consistent with the 
release of free glucose previously sequestered in muscle glycogen. Calcitonin gene-releated peptide (g-37), an amylin antagonist, prevented these 
actions. 
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1. INTRODUCTION 
Arnylin [l] is a 37 amino acid hormone synthesized 
in the pancreatic&cells which is co-secreted with insulin 
in response to nutrient stimuli [2]. In vitro, amylin has 
been shown to inhibit insulin-stimulated incorporation 
of radiolabelled glucose into glycogen in isolated skele- 
tal muscle [3,4]. Amylin was subsequently shown to 
both inhibit muscle glycogen synthase [5,6] and activate 
muscle glycogen phosphorylase. In contrast, the evi- 
dence from isolated perfused liver studies indicates that 
amylin does not have the glucagon-like ffect of activat- 
ing liver glycogen phosphorylase [7,8]. Amylin admini- 
stration during euglycemic clamp procedures in intact 
rats acutely diminishes insulin-stimulated glucose dis- 
posal [9] and increases endogenous glucose production 
[lO,l 11. Free infusions of amylin in rats result in hyper- 
lactemia and hyperglycemia. Calcitonin gene-related 
peptide (CGRP), which is -50% homologous to amylin 
[l], shares amylin’s metabolic actions on muscle, and 
the (8-37) fragment of CGRP has been shown to block 
these actions when amylin is used as an agonist [12]. 
Some authors have concluded that the acute in vivo 
insulin resistance induced by amylin (or CGRP) admin- 
istration is due to inhibition of glycogen synthesis [13- 
151. However, by measuring the incorporation of radio- 
labelled glucose into glycogen (as was done in those 
studies) it is not possible to distinguish between inhibi- 
tion of glycogen synthesis and activation of glycogenol- 
ysis. Differences between (i) the rate of incorporation of 
labelled glucose into previously unlabelled glycogen and 
*Corresponding author. 
(ii) net glycogen formation may occur because the for- 
mer is necessarily greater than or equal to zero, while 
the latter may be either positive or negative [4]. The 
present study examined the ability of amylin to activate 
glycogenolysis by prelabelling the muscle glycogen pool 
in rats with [3-3H]glucose and by observing the rate of 
appearance of tritiated water in plasma. The appear- 
ance of this label in plasma reflects labelled glucosyl 
moieties being liberated from glycogen and passing 
through the hexose + triose step in glycolysis, where 
the 3H is transferred to water. We also measured the 
appearance of tritiated glucose in plasma as a measure 
of the liberation of intact glucose molecules. Addition- 
ally, the effect of 8”7CGRP, which has been shown to 
be an effective amylin antagonist in vitro and in vivo 
[12], was tested for its ability to inhibit the observed 
effects of amylin. 
2. MATERIALS AND METHODS 
2.1. Animals 
Male Harlan-Sprague-Dawley rats (weight 352 It 85 g, age 87 f 4 
days) were housed at 22.7 f 0.8”C in a 12:12 h light/dark cycle, ex- 
periments being performed during the light cycle. They were fed 
Teklad Diet LM-485 until the day before the experiments and were 
watered ad libitmn. 
2.2. Procedures 
Rats fasted for 20.1 f 0.2 h were vigorously exercised by one hour 
of swimming in tepid water to cause a general depletion of muscle 
glycogen. They were then anesthetized with halothane, tracheoto- 
mixed, and cannulated via the femoral artery and saphenous vein. 
Body temperature was maintained by a heated operating table 
switched by a thermoregulator in response to colonic temperature. 
Mean arterial pressure was monitored and blood samples were taken 
via the arterial line. After a period of at least 90 min after surgery, at 
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a time designated as t = 0 min, a 20 min infusion of a 3 ml solution 
containing 1 g (5.56 mmol) o-glucose, 0.5 mCi [3-‘HIglucose (New 
England Nuclear) and 300 mU of recombinant human insulin (Hu- 
muhn-R, Eli Lilly, Indianapolis, IN) was begun. This regime was 
designed to rapidly replete muscle glycogen with the infused label. At 
t = 20 min, when the infusion stopped, the decay of labelled and total 
plasma glucose was followed until t = 120 min. At 120 min. rats 
received one of three treatments: 
(1) An intravenous bolus of 0.1 ml of 0.15 M saline (controls) (n = 5). 
(2) An intravenous bolus of 0.1 mg of synthetic rat amylin (Bachem, 
Torrance, CA) dissolved in 0.1 ml of saline (n = 5). 
(3) An intravenous bolus of 0.1 mg of synthetic rat amylin dissolved 
in 0.1 ml of saline, as above, but preceeded by a 0.5 mg (in 0.25 
ml) then 1.0 mg (per ml)/h primed/continuous infusion of 
8m37hCGRP (Bachem. Torrance, CA; Lot ZH425) in saline, be- 
ginning at t = 90 min and continuing until t = 240 min. 
2.3. Analyses 
Arterial samples of 125 ~1 were collected at 30 min intervals for 
determination of total plasma glucose and lactate using immobil- 
ized enzyme chemistries (YSI 2300Stat Analyzer, Yellow Springs, 
OH). Samples of 50 ~1 were collected at 30 min intervals for determi- 
nation of plasma ‘H,O and [3-‘HIglucose. Samples were deproteinized 
by perchloric acid precipitation then aliquots B-counted before and 
after evaporation to dryness [16]. Non-volatile counts remaining after 
evaporation were assumed to represent [3-‘HIglucose while the volatile 
counts lost during evaporation were assumed to represent 3H,0. At 
the end of the experiment, animals were sacrificed and livers were 
frozen for subsequent determination of glycogen content. Whole livers 
were powdered while frozen. The glycogen from _ 200 mg of such 
powder was digested in hot KOH and precipitated in ethanol as 
previously described [4]. After drying, pellets were neutralized with 0.2 
ml perchloric acid, resuspended into 1 ml of acetate buffer and the 
glycogen digested with 18.5 U/ml of amyloglucosidase (EC5 3.2.1.3, 
from Aspergillus niger, Sigma A7420, Sigma Chemical Company, St 
Louis, MO) for at least 15 min at 23°C. The supematants were assayed 
for glucose in an analyser using o-glucose oxidase immobilized enzyme 
chemistry (Analyzer model 23OOSTAT, YSI, Yellow Springs, OH). 
Purified rabbit liver glycogen (Sigma G4011) was used as a calibration 
standard. The assay was linear within the range of observed liver 
glycogen concentrations (r = 0.9994). All reagents were of analytical 
grade or better. 
2.4. Numerical Methods 
Rates of generation (or decay) of ‘H,O or [3-‘HIglucose were de- 
rived over the 30 min sampling periods. Pairwise comparisons were 
performed using t-test routines contained within the STATS module 
of SYSTAT [17]. Measures of central tendency were means f S.E.M., 
and unless otherwise stated, P = 0.05 is used as the level of signifi- 
cance. 
3. RESULTS 
Fig. 1 shows the change in total plasma glucose for 
the control and amylin treated groups. With the 20 min 
labelled glucose + insulin infusion, there was an in- 
crease in glucose to around 13-l 7 mM by the end of the 
infusion. Glucose then declined to normal levels (4-7 
mM) by t = 120 min. When saline was infused at 120 
min, plasma glucose rose slowly, commensurate with 
the responses observed previously in halothane anesthe- 
tized control animals [18]. When amylin was infused at 
120 min, plasma glucose increased rapidly (within 30 
min) and remained significantly elevated above control 
values for the next 2.5 h. 
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Fig. 1. Plasma glucose levels following the injection of insu- 
lin + labelled glucose (t = 0 mm) and of amylin (t = 120 min). The 
restoration of normal plasma glucose levels by t = 120 min is consis- 
tent with the labelled glucose being sequestered, presumably partly in 
muscle glycogen. Symbols are means f S.E.M. and asterisks indicate 
significant differences between treatment groups (P < 0.05). 
Fig. 2 shows the plasma lactate response in amylin- 
and saline-treated rats to the above procedures. All 
groups had increases in lactate during the hyperglyce- 
mic hyperinsulinemic period from 0 + 60 min consis- 
tent with previously reported lactate responses [19]. The 
increase in lactate was likely to have been a consequence 
of increased glucose- and insulin-mediated entry of glu- 
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Fig. 2. Plasma lactate levels following the injection of insu- 
lin + labelled glucose (t = 0 min) and of amylin (t = 120 min). Lactate 
levels rose during hyperglycemia, consistent with insulin- and glucose- 
driven glycolysis, and again after amylin, consistent with a glyco- 
genolyttc drive of glycolysis. Symbols are as in Fig. 1. 
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Fig. 3. Increment in plasma tritiated water after amylin injection. The 
increased appearance of tritiated water after amylin, resulting from a 
6.4-fold increase in rate of its production, is consistent with amylin- 
mediated release of labelled glucosyls sequestered inmuscle glycogen. 
Symbols are as in Fig. 1. 
case into cells, driving glycolysis to an extent that ex- 
ceeded the rate of carbohydrate oxidation. Such an ele- 
vation of glycolysis is supported by the increased rate 
of tritiated water production during that period. Ani- 
mals then injected with amylin at 120 min showed an- 
other increase in lactate, consistent with previous re- 
ports of amylin’s separate effect on lactate [18,20]. 
The tritium counts assigned to plasma water are 
shown for amylin and saline injected rats in Fig. 3. 
Following the rapid generation of 3H,0 during the pe- 
riod of hyperinsulinemia and hyperglycemia, rate of 
‘H,O production became more steady. At t = 120 min, 
saline injection did not appreciably change this rate. In 
contrast, amylin administration increased the rate of 
3H,0 generation 6.4-fold within 30 min of administra- 
tion (P < 0.02). 
The tritium counts assigned to [3-3H]glucose are 
shown for amylin and saline injected rats in Fig. 4. As 
predicted, counts rose with the initial infusion and then 
declined, consistent with the labelled glucose either 
being metabolized through glycolysis, or being seques- 
tered primarily as muscle glycogen. When amylin was 
administered at t = 120 min, there was a 35% increase 
in tritium assignable to plasma [3-3H]glucose over the 
next 30 min. In the same period, plasma [3-3H]glucose 
declined by 10% in control animals (P < 0.02). 
Liver glycogen content was generally low (less than 
5 mg/g), consistent with previous reports in fasted, gly- 
cogen depleted animals. Levels in amylin-treated rats 
were 2.8-fold higher than controls, but levels were 
highly variable and were not statistically different 
(P = 0.1). 
sm37hCGRP preinfusion inhibited all the observed ac- 
tions of amylin. The amylin-induced change in plasma 
glucose and lactate was abrogated by 8-37hCGRP such 
that these responses were not measurably different from 
those of control animals, as previously reported [12]. 
Preinfusion of 8-37hCGRP reduced the amylin-induced 
acceleration in rate of appearance of plasma 3H,0 by 
over 50% and suppressed the amylin-induced release of 
[3-3H]glucose. 
4. DISCUSSION 
In the present study, we sought to follow the fate of 
labelled glucose moieties that could be incorporated 
into muscle glycogen. [3-3H]glucose has the advantage 
that label is not lost during the futile cycling between 
glucose-6-phosphate and fructose-6-phosphate as oc- 
curs with [Z3H]glucose [21]. It also has the advantage 
that the label is lost to water during the essentially irre- 
versible hexose + triose step in glycolysis [21], so that 
the appearance of tritiated water is a measure of glyco- 
lytic rate [ 161. Because the specific activity or distribu- 
tion of label within the glycogen pool was unknown, it 
was not possible to quantitatively determine glycolytic 
or other fluxes. However, it was assumed that in groups 
of animals identically pretreated, the disposition of label 
within glycogen would be similar, so that qualitative 
inter-group comparisons could be made. When amylin 
was administered, there was a 6.4-fold increase in the 
rate of tritiated water production. 
Glycogen synthesis and degradation appear to occur 
concurrently [22] so that net production or loss of glyco- 
gen reflects the balance of these two processes. Amylin- 
stimulation of CAMP in skeletal muscle [23,24] is likely 
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Fig. 4. Increment in plasma [3-‘HIglucose after amylin injection. Since 
it is irreversibly metabolized uring glycolysis, the reappearance of 
[3-‘HIglucose in plasma after amylin injection is difficult to explain by 
a mechanism other than release from intracellular glycogen stores. 
Symbols are as in Fig. 1. 
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to underly its reciprocal inhibition of glycogen synthase 
[5] and activation of glycogen phosphorylase [6] and 
thus promote net loss of muscle glycogen. Inhibition of 
synthase, with consequent diversion of glucose-6-phos- 
phate into glycolysis has previously been offered as 
an explanation of the increase in tritiated water evoked 
by CGRP in a preparation similarly preinfused with 
[3-3H]glucose during hyperinsulinemia [151. However, 
since amylin at the doses used in the present report 
inhibits glucose uptake by over 50%, and carbohydrate 
storage represents no more than about 70% of glucose 
disposal [25], it can be estimated that a diversion of 
glucose from carbohydrate storage into glycolysis could 
account for no more than a 1.7-fold increase in 3H,0 
generation; however, the observed amylin-evoked in- 
crease was 6.4-fold. On this basis we conclude that the 
increased generation of titriated water after amylin in 
these experiments was more a consequence of increased 
glycogenolysis providing labelled glucose to glycolysis 
than a consequence of decreased glycogen synthesis di- 
verting incoming labelled glucose into the glycolytic 
pathway. 
Other studies point to a dominant effect of amylin- 
stimulated glycolysis. [3-3H]glucose is sequestered in 
muscle glycogen followed insulin stimulation [ 161, so 
amylin activation of phosphorylase (and inhibition of 
synthase) would flood the cell with labelled hexose 
monophosphates. Amylin-stimulation of CAMP would 
also activate phosphofructokinase via the fructose 2,6- 
bisphosphate regulatory mechanism, stimulating glyco- 
lysis and the observed generation of 3H,0 and lactate. 
In regard to lactate production, isolated extensor dig- 
itorum longus muscles incubated with [U-14C]glucose 
and exposed to CGRP (an amylin agonist) produced 
lactate whose specific activity was significantly diluted 
from that expected if it were derived from transported 
labelled glucose; but the dilution of specific activity fits 
with dilution of label by glucose moieties released from 
the endogenous glycogen pool [26]. Further, total enzy- 
matic activity of glycogen phosphorylase is 12-85 times 
higher than that of glycogen synthase in muscle [27,28], 
so it is expected that changes in glycogenolytic flux will 
outweigh changes in glycogenic flux following near 
maximally effective stimuli (such as are likely to be 
present in the present experiments). These considera- 
tions do not preclude the possibility that in other condi- 
tions such as at lower amylin concentrations, the rela- 
tive impact on glycogen synthesis and glycogen degra- 
dation could be different [ 151. 
The data shown in Fig. 4 are surprising, in that they 
indicate amylin-stimulated release of free (labelled) glu- 
cose from a sequestered (non-plasma) pool. How could 
amylin administration produce free glucose? One possi- 
bility is that labelled glucose incorporated into liver 
glycogen could be released and pass through glucose-6- 
phosphatase to re-emerge from the liver as labelled glu- 
cose. However, amylin does not appear to have such 
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action at the liver, as determined in isolated perfused 
preparations [7,8]. Indeed, liver glycogen measurements 
in the present study suggest he opposite - that there 
may have been a gain in liver glycogen during amylin 
administration. A similar gain in liver glycogen was 
observed by Cori et al. following peripheral glycogenol- 
ysis after epinephrine administration [29]. An alterna- 
tive explanation is that the labelled glucose reappearing 
in plasma was derived from muscle glycogen. Release 
of free glucose from muscle has been proposed to occur 
through the following mechanism [30]. Although the 
glycogen chain consists mainly of a- 1,4 glycosidic link- 
ages, about 8-10% of glucosyls are represented as a-l,4 
a-1,6 branches. While the straight chain linkages are 
broken by glycogen phosphorylase and phosphor- 
ylated, the branch glycosyl requires a separate debran- 
thing enzyme system [31]. The release of such a moiety 
consumes water and releases free glucose. Since intra- 
cellular glucose-6-phosphate is high during amylin-in- 
duced glycogenolysis [9], hexokinase is likely to be in- 
hibited. Because its phosphorylation was inhibited and 
its rate of production was high, free intracellular glucose 
could accumulate. Glucose transporters are able to 
transport in either direction, so the intracellular glucose 
generated from glycogen debranching could result in 
net glucose eftlux from muscle. 
The contribution of muscle glycogenolysis, whether 
induced by amylin, exercise, catecholamines, hypoxia, 
or other mechanisms, to endogenous glucose produc- 
tion warrants further consideration. 
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